Edwards Lifesciences Corporation (EW)
收市後：
| 前收市價 | 81.08 |
| 開市 | 81.26 |
| 買盤 | 81.41 x 2200 |
| 賣出價 | 82.06 x 900 |
| 今日波幅 | 81.03 - 82.46 |
| 52 週波幅 | 67.13 - 131.10 |
| 成交量 | |
| 平均成交量 | 3,585,552 |
| 市值 | 50.438B |
| Beta 值 (5 年，每月) | 1.01 |
| 市盈率 (最近 12 個月) | 33.09 |
| 每股盈利 (最近 12 個月) | 2.47 |
| 業績公佈日 | 2023年4月24日 - 2023年4月28日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 87.62 |
- Insider Monkey
Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW) Q4 2022 Earnings Call Transcript January 31, 2023 Operator: Greetings, and welcome to the Edwards Lifesciences Fourth Quarter 2022 Earnings Conference Call. Please note, this conference is being recorded. I will now turn the conference over to our host, Mark Wilterding, Senior Vice President of Investor Relations and Treasurer. Thank you. […]
- Benzinga
Edwards Lifesciences Q4 Earnings Beats Street Estimates, Expects Easing Of Macro Headwinds Later In 2023
Edwards Lifesciences Corp (NYSE: EW) reported Q4 adjusted EPS of $0.64, up 25% Y/Y and higher than the consensus of $0.61. The company reported Q4 revenues of $1.35 billion, up 1% and 7% on constant currency, beating the consensus of $1.33 billion. While TAVR sales remained flat year over year, Edwards reported 1% growth for its structural heart business. It attributed that bump to its Resilia technologies launch and Mitris surgical mitral valve. Outlook: Edwards Lifesciences reaffirmed its FY23
- Insider Monkey
Multiple Reasons for the Decline of Edwards Lifesciences Corporation (EW) Stock
Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P […]
